Our Work
Founded in 2009 because the most effective forms of reversible contraception were too expensive and out of reach, Medicines360 is a nonprofit pharmaceutical organization that prioritizes women over profit to ensure equitable access to medicines.
Today, our focus is to develop and provide a broader range of high-quality products that will help fill gaps in women’s health. Our experience in drug development, clinical trial research, and regulatory affairs makes us uniquely positioned to address the high cost of medicines.
U.S. Accomplishments
Medicines360 conducted the United States’ largest and most diverse Phase 3 clinical trial ever on a hormonal IUD. To date, in collaboration with our commercial partner, we have made our hormonal IUD available to more than 1.5 million women throughout the United States. Our work in the public sector has also served approximately 2,500 publicly funded clinics throughout the U.S., saving the public healthcare system over an estimated $166 million.
Despite the increased number of women who have been able to obtain an affordable contraceptive option, there is more to be done to truly realize equitable access to the medicines that women need.
Increased philanthropic investment to offset the high cost of product development, research, and regulatory fees can allow the nonprofit pharmaceutical industry to fill gaps and ensure equitable access to medicines.
Our Global Work
We work with global and local distribution partners to make AVIBELA4 available to women in LMICs, including ministries of health, global procurement agencies and wholesalers, NGOs, and humanitarian organizations. Together, we can expand equitable access to new innovations in women’s health globally.
Advancing a New "Nonprofit Pharma" Model
We believe nonprofit pharma can help transform the healthcare system by ensuring more equitable access to life-altering medicines.
Nonprofit Pharma Model
Our Strategic Priorities
Complex problems require multi-faceted, long-term solutions. As a social enterprise, we are driven to help make equitable access to medicines a reality for women. Our organization has developed momentum to address one of the most pressing issues that plague our current system – the high cost of drugs that prohibits access for many women. We will continue engaging with stakeholders and philanthropic donors to bring new and expanded resources to our work in product development, policy advocacy, and public sector engagement.
Since our founding in 2009, we have learned critical lessons that have informed our priorities for the next chapter in our pursuit of equitable access.
Key Priorities
Grow Our Impact
Expand the portfolio of women’s health products that increase access and/or healthcare choice
Capitalize on Our Success
Maximize our impact and act as a catalyst for change
Deliver on Medicines360’s Promise
Expand AVIBELA's global impact
Create Points of Leverage In the Community
Develop strategic relationships to acquire pipeline products and capital for R&D
Collaboration,
The Pathway to Impact
Closing gaps in equitable access is a significant challenge and cannot be solved by any one organization alone. It is only through working with others that we can achieve meaningful change. As such, we are proud of the relationships we have formed with organizations to develop and distribute products in the U.S. and globally. These collaborations reflect diverse, yet complementary organizations that collectively contribute to support and uplift women.
Stay Informed
Sign up to receive updates about our work focused on improving women’s health.
Medicines360 respects individual privacy and values the confidence of our customers. By submitting the information above, you understand this information will be used in accordance with our Privacy Policy. You further acknowledge that Medicines360 and its business partners may send you relevant information regarding disease education, as well as information on related products or services, and for marketing or other informational purposes. You may opt out of receiving such communications by unsubscribing directly from emails sent to you or sending an email request to the address below. Your choices regarding our use and disclosure of your Personal Information:
We give you many choices regarding our use and disclosure of your Personal Information for marketing purposes. You may opt out from:
- Receiving marketing-related emails from us: If you no longer want to receive marketing-related emails from us on a going-forward basis, you may opt out of receiving these marketing-related emails by following the instructions included in email communications from us, or contact us at: access@medicines360.org.
- Our sharing of your Personal Information with affiliates for their marketing purposes: If you would prefer that we do not share your Personal Information on a going-forward basis with our affiliates for their marketing purposes, you may opt out of this sharing by notifying us sending us a written statement to: Medicines360 Website, 49 Stevenson St | Suite 1100 | San Francisco, CA 94105 USA, by following the instructions included in email communication you received from us, or by contacting us at: access@medicines360.org.
- Kaiser Family Foundation. Women’s Health Insurance Coverage. Accessed June 2022
- The Lancet. Measuring contraceptive method mix, prevalence, and demand satisfied by age and marital status in 204 countries and territories, 1970–2019: a systematic analysis for the Global Burden of Disease Study 2019. Accessed August 2022
- Sully EA et al., Adding It Up: Investing in Sexual and Reproductive Health 2019, New York: Guttmacher Institute, 2020, https://www.guttmacher.org/fact-sheet/investing-sexual-and-reproductive-health-low-and-middle-income-countries
- AVIBELA is not available in the United States. In the US, our hormonal IUD is marketed under the name LILETTA®.
